Pfizer Inc. (PFE) — closed signal from July 22, 2025
Partial Published before the outcome was known, scored automatically when the window closed on October 20, 2025.
Predicted vs. what happened
What happened
Reached 63% of the predicted growth at its peak, without hitting the target.
The thesis — published July 22, 2025
Pfizer’s stock is cheap because demand for Covid products is fading, but buying Seagen could add big cancer drug sales by 2030. The price just climbed above its recent average on the busiest trading day since April, showing new interest. Two key dates-earnings on July 30 and cancer-drug data on Sept 6-could spark more gains. While you wait, the 5.6% dividend keeps paying you.
Primary drivers
- Lowered forecasts make a July 30 earnings surprise more likely
- Sept 6 cancer drug results could revive excitement about the Seagen buy
- Share price climbed above its recent average on record trading, hinting demand
- A solid 5.6% dividend, paid from free cash flow, supports the stock price
How it played out
PFE: target was missed after a 12.5% peak gain
Lyra published PFE at $24.19 on 2025-07-22 with expected growth of 20%. The thesis pointed to lowered forecasts before July 30 earnings, possible cancer drug results on Sept. 6, heavier trading above a recent average, and a 5.6% dividend paid from free cash flow.
Inside the window, PFE rose to a peak of $27.21 on 2025-10-03, a 12.5% gain. The target was $28.05, and the stock never reached it. By 2025-10-20, it ended at $24.26. The thesis partially played out: the price rose, but it stayed below the target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.